CN118525016A - 蛋白酪氨酸磷酸酶抑制剂及其使用方法 - Google Patents

蛋白酪氨酸磷酸酶抑制剂及其使用方法 Download PDF

Info

Publication number
CN118525016A
CN118525016A CN202280088273.9A CN202280088273A CN118525016A CN 118525016 A CN118525016 A CN 118525016A CN 202280088273 A CN202280088273 A CN 202280088273A CN 118525016 A CN118525016 A CN 118525016A
Authority
CN
China
Prior art keywords
methyl
fluoro
dihydro
hydroxy
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280088273.9A
Other languages
English (en)
Chinese (zh)
Inventor
A·博丹
E·P·法尼
J·M·弗罗斯特
P·R·基姆
Z·熊
N·A·巴顿
C·A·M·卡里奥-芒福德
C·P·麦克马洪
G·纳诺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Calico Life Sciences LLC
Original Assignee
AbbVie Inc
Calico Life Sciences LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Inc, Calico Life Sciences LLC filed Critical AbbVie Inc
Publication of CN118525016A publication Critical patent/CN118525016A/zh
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433Thidiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202280088273.9A 2021-11-11 2022-11-10 蛋白酪氨酸磷酸酶抑制剂及其使用方法 Pending CN118525016A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163278339P 2021-11-11 2021-11-11
US63/278339 2021-11-11
PCT/US2022/049584 WO2023086498A1 (en) 2021-11-11 2022-11-10 Protein tyrosine phosphatase inhibitors and methods of use thereof

Publications (1)

Publication Number Publication Date
CN118525016A true CN118525016A (zh) 2024-08-20

Family

ID=84689141

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280088273.9A Pending CN118525016A (zh) 2021-11-11 2022-11-10 蛋白酪氨酸磷酸酶抑制剂及其使用方法

Country Status (8)

Country Link
US (1) US20250019374A1 (https=)
EP (1) EP4430038A1 (https=)
JP (1) JP2024543452A (https=)
CN (1) CN118525016A (https=)
AU (1) AU2022387106A1 (https=)
CA (1) CA3236854A1 (https=)
MX (1) MX2024005658A (https=)
WO (1) WO2023086498A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20252789A1 (es) 2023-05-24 2025-12-22 Kumquat Biosciences Inc Compuestos heterociclicos y usos de estos
WO2025026158A1 (zh) * 2023-07-28 2025-02-06 杭州中美华东制药有限公司 具有ptpn2抑制作用的化合物及其用途
WO2025242216A1 (zh) * 2024-05-24 2025-11-27 杭州百新生物医药科技有限公司 吲哚啉类化合物及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA94921C2 (en) * 2005-12-08 2011-06-25 Новартис Аг 1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as ptp-as inhibitors
UA94724C2 (en) * 2005-12-08 2011-06-10 Новартис Аг Thiadiazolidinone derivatives as antidiabetic agents
BR112020026086A2 (pt) * 2018-06-21 2021-03-23 Calico Life Sciences Llc inibidores da proteína tirosina fosfatase e métodos de uso destes
IL286373B2 (en) * 2019-03-14 2026-03-01 Calico Life Sciences Llc Protein tyrosine phosphate inhibitor compounds and uses thereof
CA3162069A1 (en) * 2019-12-18 2021-06-24 Elliot P. Farney Protein tyrosine phosphatase inhibitors and methods of use thereof

Also Published As

Publication number Publication date
WO2023086498A1 (en) 2023-05-19
AU2022387106A1 (en) 2024-05-23
EP4430038A1 (en) 2024-09-18
CA3236854A1 (en) 2023-05-19
US20250019374A1 (en) 2025-01-16
JP2024543452A (ja) 2024-11-21
MX2024005658A (es) 2024-08-06

Similar Documents

Publication Publication Date Title
US12595265B2 (en) Inhibitors of activin receptor-like kinase
EP3728238B1 (en) Sulphonyl urea derivatives as nlrp3 inflammasome modulators
EP3455204B1 (en) Cyclopropyl-amide compounds as dual lsd1/hdac inhibitors
CN112689638B (zh) 作为lsd1抑制剂的环丙胺类化合物及其应用
CN118525016A (zh) 蛋白酪氨酸磷酸酶抑制剂及其使用方法
JP4199298B2 (ja) Pparアゴニスト活性を有する誘導体
CN114173803A (zh) 氨基酸化合物的剂型和方案
WO2019157879A1 (zh) 作为trk抑制剂的杂环化合物
CN114685531B (zh) 四并环化合物及其药物组合物和应用
KR20230142745A (ko) Cdk2 억제제 및 그의 사용 방법
WO2021161105A1 (en) P2x3 modulators
TW201803842A (zh) 胺基酸衍生物之前藥
IL295196A (en) macrocyclic rip2-kinase inhibitors
JP5665057B2 (ja) Hdl上昇剤
CN118556055A (zh) 蛋白酪氨酸磷酸酶抑制剂及其使用方法
TW202435866A (zh) 小分子fsh受體調節劑
WO2025175247A1 (en) Imidazo-pyrazine derivatives and their use in the treatment of neurologic disorders
WO2024152995A1 (zh) 一种大环类细胞周期蛋白抑制剂及其制备方法和应用
HK40070149A (en) Dosage forms and regimens for amino acid compounds
HK40008443A (en) Imidazopyrrolopyridine as inhibitors of the jak family of kinases
HK1256634A1 (zh) 吡唑化合物及其制备和使用方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination